Kestra Private Wealth Services LLC Acquires 1,523 Shares of Organon & Co. (NYSE:OGN)

Kestra Private Wealth Services LLC raised its stake in shares of Organon & Co. (NYSE:OGN) by 7.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 21,216 shares of the company’s stock after acquiring an additional 1,523 shares during the period. Kestra Private Wealth Services LLC’s holdings in Organon & Co. were worth $306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. New York State Teachers Retirement System increased its position in shares of Organon & Co. by 20.1% during the 4th quarter. New York State Teachers Retirement System now owns 348,226 shares of the company’s stock valued at $5,021,000 after purchasing an additional 58,321 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Organon & Co. by 417.8% in the fourth quarter. State of Alaska Department of Revenue now owns 157,249 shares of the company’s stock worth $2,267,000 after acquiring an additional 126,882 shares during the period. KLCM Advisors Inc. grew its holdings in Organon & Co. by 60.4% during the 4th quarter. KLCM Advisors Inc. now owns 999,099 shares of the company’s stock worth $14,407,000 after acquiring an additional 376,055 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in Organon & Co. by 59.1% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 221,461 shares of the company’s stock valued at $3,193,000 after purchasing an additional 82,239 shares during the period. Finally, UBS Group AG raised its holdings in shares of Organon & Co. by 88.3% in the 3rd quarter. UBS Group AG now owns 657,912 shares of the company’s stock valued at $11,421,000 after purchasing an additional 308,470 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

Insider Buying and Selling at Organon & Co.

In other news, insider Kirke Weaver purchased 2,720 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the transaction, the insider now owns 15,181 shares in the company, valued at $278,723.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.17% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

OGN has been the topic of several recent research reports. Piper Sandler increased their target price on Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, April 29th. The Goldman Sachs Group increased their price objective on shares of Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, May 3rd.

Organon & Co. Trading Down 0.1 %

OGN opened at $20.37 on Thursday. The firm has a 50 day moving average of $18.30 and a two-hundred day moving average of $15.82. The firm has a market capitalization of $5.24 billion, a PE ratio of 5.00, a P/E/G ratio of 0.88 and a beta of 0.81. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.08.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. As a group, analysts predict that Organon & Co. will post 4.1 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 13th. Investors of record on Monday, May 13th will be given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 5.50%. The ex-dividend date is Friday, May 10th. Organon & Co.’s dividend payout ratio is currently 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.